In conclusion, the present study reveals a previously unrecognized role of diosmin, a conventional drug features long-time clinical use and safeness, in improving insulin sensitivity by blocking PPARγ phosphorylation and reducing obesity without the side effects of classic PPARγ full agonists. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.